Core Viewpoint - Chenxin Pharmaceutical (603367.SH) announced a share reduction by a major shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd., which sold 1 million shares, representing 0.221% of the company's total share capital [1] Shareholder Activity - On September 22, 2025, Shijiazhuang Four Pharmaceutical Co., Ltd. reduced its holdings from 27,661,441 shares to 26,661,441 shares [1] - The shareholding percentage decreased from 6.11% to 5.89%, marking a change that touches the 1% threshold [1]

Core Viewpoint - Chenxin Pharmaceutical has shown significant stock performance with a year-to-date increase of 60.13%, despite a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - On September 18, Chenxin Pharmaceutical's stock rose by 2.07%, reaching 21.65 CNY per share, with a trading volume of 1.59 billion CNY and a turnover rate of 1.64%, resulting in a total market capitalization of 9.802 billion CNY [1]. - The stock has experienced a 1.26% increase over the last five trading days, a 27.83% decrease over the last 20 days, and a 56.32% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on September 3, where it recorded a net purchase of 51.8339 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Chenxin Pharmaceutical reported a revenue of 1.740 billion CNY, a year-on-year decrease of 15.97%, and a net profit attributable to shareholders of 229 million CNY, down 15.23% year-on-year [2]. - The company has distributed a total of 1.112 billion CNY in dividends since its A-share listing, with 548 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Chenxin Pharmaceutical was 35,900, an increase of 68.07% from the previous period, with an average of 12,602 shares held per shareholder, a decrease of 40.50% [2]. - Hong Kong Central Clearing Limited is the seventh-largest circulating shareholder, holding 6.9075 million shares, an increase of 1.9689 million shares from the previous period [3].

Company Overview - Chanshin Pharmaceutical Co., Ltd. is located at No. 16 Tongji Road, High-tech Zone, Jining City, Shandong Province, established on November 6, 1998, and listed on September 29, 2017 [2] - The company's main business involves research, development, and production of chemical drug formulations, with revenue composition as follows: large-volume injections 42.66%, small-volume injections 29.80%, oral solid preparations 13.98%, drops 4.31%, lyophilized powder injections 3.68%, ointments 3.43%, raw materials 1.35%, rinsing agents 0.59%, and others 0.20% [2] - Chanshin Pharmaceutical belongs to the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical formulations, with concepts including heparin, anti-influenza, small-cap, biomedicine, and innovative drugs [2] Financial Performance - For the first half of 2025, Chanshin Pharmaceutical achieved operating revenue of 1.74 billion yuan, a year-on-year decrease of 15.97%, and a net profit attributable to shareholders of 229 million yuan, a year-on-year decrease of 15.23% [2] - The company has distributed a total of 1.112 billion yuan in dividends since its A-share listing, with 548 million yuan distributed in the last three years [3] Stock Performance - As of September 17, Chanshin Pharmaceutical's stock price was 21.17 yuan per share, with a market capitalization of 9.585 billion yuan [1] - The stock has increased by 56.58% year-to-date, but has seen a decline of 30.93% over the past 20 days [1] - The company has appeared on the trading leaderboard four times this year, with the most recent appearance on September 3, where it recorded a net purchase of 51.83 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders for Chanshin Pharmaceutical was 35,900, an increase of 68.07% from the previous period, with an average of 12,602 circulating shares per person, a decrease of 40.50% [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 6.9075 million shares, an increase of 1.9689 million shares from the previous period [3]

Meeting Overview - The second extraordinary general meeting of shareholders was held on September 16, 2025, at the company's office in Jining, Shandong Province [2] - The meeting was convened by the board of directors and chaired by Chairman Du Zhenxin, utilizing a combination of on-site and online voting methods [2][3] Attendance and Voting - All current directors (9) and supervisors (3) attended the meeting, along with the board secretary and other senior management [3][4] - No resolutions were rejected during the meeting [2] Resolutions Passed - The following key resolutions were approved: - Amendments to the Articles of Association and its attachments [3] - Amendments to the Rules of Procedure for Shareholders' Meetings [3] - Amendments to the Rules of Procedure for Board Meetings [4] - Amendments to the Independent Director Work System [4] - Establishment of Implementation Details for Cumulative Voting System [4] - Amendments to the Decision-Making System for External Guarantees [4] - Amendments to the Management System for the Appointment of Accounting Firms [4] - Establishment of the Compensation Management System for Directors and Senior Management [4] - Establishment of Behavior Norms for Controlling Shareholders and Actual Controllers [4] - Amendments to the Related Party Transaction Decision-Making System [5] - Amendments to the Fundraising Management Measures [5] - Abolishment of the Rules of Procedure for Supervisory Meetings [5] - Resolution to abolish the supervisory board and supervisors [5] - Resolution to permanently supplement remaining funds from fundraising projects into working capital [5] Legal Verification - The meeting was witnessed by lawyers from Shandong Guoyao Qindao (Jinan) Law Firm, confirming that the meeting's procedures complied with relevant laws and regulations [6] - The legal opinion concluded that the qualifications of the convenor and attendees were valid, and the voting procedures and results were lawful and effective [6]

证券代码：603367 证券简称：辰欣药业 公告编号：2025-050 辰欣药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 16 日 (一)非累积投票议案 1、 议案名称：《关于修订＜公司章程＞及其附件的议案》 1.01、《关于修订＜公司章程＞的议案》 (二)股东大会召开的地点：山东省济宁市高新区同济路 16 号辰欣药业股份有限 公司一园区办公楼六楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 209 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 204,974,370 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 45.2727 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会 ...

山东国曜琴岛(济南)律师事务所 关于辰欣药业股份有限公司 2025年第二次临时股东大会的 法律意见书 山东国曜 律师事务所 号国曜琴岛律师楼 济南市历下 7665 电话:0531-58681777 二〇二五年九月 始于1956 · 缔造百年律所 ENTURY-OLD LAW FIRM 始于1956 · 缔造百年律所 山东国曜琴岛(济南)律师事务所 关于辰欣药业股份有限公司 2025年第二次临时股东大会的法律意见书 【2025】国曜琴岛(济南)非诉字第294号 致:辰欣药业股份有限公司 山东国曜琴岛(济南)律师事务所(以下简称"本所")接受辰欣药业股份 有限公司(以下简称"辰欣药业"、"公司")的委托,指派本所律师出席公司 于2025年9月16日召开的2025年第二次临时股东大会(以下简称"本次股东大会" ）。本所律师根据《中华人民共和国证券法》(以下简称"《证券法》")、《 中华人民共和国公司法》(以下简称"《公司法》")、《上市公司股东会规则》 等现行有效的法律、法规、规范性文件以及《辰欣药业股份有限公司章程》（以 下简称"《公司章程》")的有关规定,就本次股东大会的相关事宜出具本法律 意见书。 为出具本法 ...

Group 1 - The Jining government is focusing on building a modern pharmaceutical industry hub, highlighted by a recent press conference featuring key local pharmaceutical companies [1][3] - The "chain leader system" has been adopted as a key initiative to promote industrial economic development, leading to positive monthly progress in the pharmaceutical sector [3] - Jining has a solid foundation in the modern pharmaceutical industry with 67 large-scale enterprises, including 6 chain leader companies and various recognized specialized firms [3] Group 2 - The modern pharmaceutical industry chain in Jining consists of three core sectors: chemical pharmaceuticals, modern traditional Chinese medicine, and medical devices [4] - The chemical pharmaceutical sector focuses on an integrated development model of raw materials and formulations, leveraging cost-effectiveness and quality advantages [4] - The modern traditional Chinese medicine sector aims to create a distinctive brand based on local aquatic medicinal resources, while the medical device sector is expanding into high-end medical equipment [4] - Future developments will target breakthroughs in biopharmaceuticals, modernization of traditional Chinese medicine formulations, and high-end medical device research [4]

Core Insights - Chenxin Pharmaceutical is a comprehensive pharmaceutical enterprise engaged in R&D, production, and sales, listed on the Shanghai Stock Exchange in September 2017 [1] - The company has established a strong production capacity, leading in both large-volume and small-volume injection production in China [1][3] - R&D innovation is a core strategic focus, with significant investment in technology and collaboration with over 30 research institutions [4] Group 1: Company Overview - Chenxin Pharmaceutical has over 5,000 employees and offers more than 400 specifications of various dosage forms [1] - The company has completed an industrial layout with four major production bases and five industrial parks [3] - R&D personnel exceed 600, with over 70% holding advanced degrees, and R&D investment accounts for approximately 10% of revenue [3] Group 2: R&D and Innovation - The company invests nearly 400 million yuan annually in R&D innovation, establishing a solid foundation for technological competitiveness [4] - Chenxin focuses on high-end generic drugs, OTC external medications, innovative drugs, and special medical foods, creating a virtuous cycle of production and development [4][5] - Future goals include advancing 1-2 new Class 1 drugs into clinical Phase I each year and launching one Class 1 drug within five years [5] Group 3: Production and Technology - Production is the foundational aspect of Chenxin, emphasizing large-scale capacity, intelligent manufacturing, and standardized quality control [6] - The company integrates advanced technologies such as big data and AI into its manufacturing processes, aiming for a smart manufacturing benchmark in the pharmaceutical industry [6] - Annual investments of no less than 300 million yuan will be directed towards technological upgrades and automation [6] Group 4: Marketing and Industry Chain - The marketing system effectively translates the company's internal value into market results, covering hospitals, grassroots medical institutions, and retail terminals [8] - Chenxin aims to enhance its competitive advantage by integrating raw materials and formulations, ensuring product quality and supply chain stability [8] - The company is exploring new paths in health management and elder care services, expanding its business boundaries [8]

Group 1 - The special medical food market has significant potential, with Shandong province being an early player and ranking second in the number of production enterprises nationwide [2] - Chenxin Pharmaceutical has been deeply involved in the special medical food sector for nearly 10 years, obtaining five product registration approvals and collaborating with 200-300 hospitals [2][3] - The company has broken the long-standing monopoly of international corporations in the field by securing the first batch of national approvals for liquid full-nutrition special medical food [2][4] Group 2 - The high barriers to entry and strict regulations characterize the special medical food industry, with Chenxin developing a "step sterilization process" to balance sterilization effectiveness and nutrient retention [3][4] - The company has successfully developed a unique oil-water online mixing technology to address challenges in product formulation, ensuring stability and quality [4][7] - Chenxin's liquid special medical food is designed for individuals with restricted eating capabilities and can be administered via nasal feeding [3][4] Group 3 - The company has strengthened its R&D capabilities, with some products being prioritized for expedited review by the National Market Supervision Administration [5][6] - The "Xinsulin special medical use diabetes full-nutrition formula food" is set to enter a fast-track approval process, significantly reducing the approval time from about one year to six months [6] - The R&D for diabetes-specific nutrition has taken nearly two years, highlighting the complexity and challenges in developing liquid formulations compared to powder products [6][7] Group 4 - Chenxin has established a rigorous production system, utilizing automated production lines and a three-stage air filtration system to ensure product quality [3][7] - The company collaborates with various research institutions to enhance its R&D and industrialization capabilities in the special medical food sector [7]

辰欣药业股份有限公司 2025 年第二次临时股东大会会议资料 辰欣药业股份有限公司 2025 年第二次临时股东大会 会议资料 二 0 二五年九月 1 / 14 辰欣药业股份有限公司 2025 年第二次临时股东大会会议资料 辰欣药业股份有限公司 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，根据《中华 人民共和国公司法》《公司章程》制定本须知，望出席辰欣药业股份有限公司（以下简 称"公司"或"辰欣药业"）股东大会的全体人员遵照执行。 一、参会资格：本次股东大会股权登记日下午收市后在中国证券登记结算有限责任 公司上海分公司登记在册的公司股东。 二、会议期间全体出席会议人员应以维护股东合法权益，确保大会正常进行，提高 议事效率为原则，认真履行法定职责。请与会者维护现场秩序，会议期间请勿大声喧哗。 三、为保证股东大会的严肃性和正常秩序，除依法出席会议的公司股东（或其代理 人）、董事、监事、董事会秘书、高级管理人员、聘请的律师和董事会邀请参会的人员、 会务工作人员外，公司有权依法拒绝其他人士入场。 四、由公司董事会秘书负责本次大会的会务事宜。 五、出席本次会议的股 ...